Axsome Therapeutics, Inc.
AXSM
Rank in Stocks
#2390
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Share Price
$157.29
Last synced: 2026-10-16
Market Cap
$8.24B
Change (1 day)
-2.78%
Change (1 year)
22.94%
Country
US
Trade Axsome Therapeutics, Inc. (AXSM)
Category
Healthcare
Operating Margin for Axsome Therapeutics, Inc. (AXSM)
Operating Margin as of October 2026 TTM: -24.28%
According to Axsome Therapeutics, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is -24.28%. At the end of 2023 the company had an Operating Margin of -85.67%.
Operating Margin history for Axsome Therapeutics, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -24.28% | -66.62% |
| 2024 | -72.74% | -15.09% |
| 2023 | -85.67% | -75.71% |
| 2022 | -352.74% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -101.59% |
US
|
|
| -149.01% | -93.86% |
US
|
|
| 25.57% | -101.05% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -101.19% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.